Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

Abstract

Background and aim. Sodium-glucose cotransporter (SGLT) 2 is a specifically expressed transporter in the kidney that plays an important role in renal glucose reabsorption, and its inhibition may present a novel therapeutic strategy for treating diabetes. Here, we pharmacologically characterized YM543, a newly synthesized SGLT2 selective inhibitor to test this theory. Results. In vitro studies revealed that YM543 potently and selectively inhibited mouse and human SGLT2 activities at nanomolar ranges. In vivo single oral administration of YM543 dose-dependently and significantly reduced blood glucose levels and improved glucose tolerance with a concomitant increase in urinary glucose excretion in KK/A^y type 2 diabetic mice, effects that were sustained even after 12 h. Repeated once-daily oral administration of YM543 for 5 weeks significantly reduced hyperglycemia in type 2 diabetic mice. In addition, combination treatment of YM543 with rosiglitazone or metformin additively improved diabetic symptoms. In contrast, YM543 did not affect normoglycemia at pharmacological doses in normal mice. Conclusions. Results from the present study suggest that YM543 is an orally active SGLT2 selective inhibitor which reduces hyperglycemia with a concomitant increase in urinary glucose excretion, indicating its promise as an effective treatment against type 2 diabetes.

• Sodium-glucose cotransporter 2
• Hyperglycemia
• Urinary glucose excretion
• Diabetes

ACKNOWLEDGMENTS

The authors acknowledge Drs. Isao Yanagisawa, Seitaro Mutoh, Yasuaki Shimizu, Wataru Uchida, and Shinichi Tsukamoto (Astellas Pharma Inc.) for their valuable comments and continuing encouragement.

Declaration of Interest:

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.